Broker & Partner Portal

● System Operational
Active Deals
14
↑ 3 vs last month
Registered AUM
$2.4B
Across 8 divisions
Avg. Response Time
4.2h
↑ 18% efficiency
NDA Status
Active
Expires: 14 Mar 2027
Deal Pipeline
ID Deal / Target Division Value Stage Priority
AZ-8842
Meridian Fusion Systems
Acquisition Target
Energy & Power $480M Due Diligence High
AZ-9105
Orbital Logistics Network
Joint Venture
Aerospace $1.2B Committee Review High
AZ-9312
NeuroGen Therapeutics
Series C Intro
Health Sciences $320M Initial Screening Med
AZ-9401
Pacific AgriTech Holdings
Asset Sale
Agritech $89M Closed / Commingled Low
Recent Activity
View All
📄
NDA executed for Project Chimera. Secure vault access granted.
2 hours ago
🤝
Deal committee call scheduled with Zenth Capital team.
Yesterday, 14:00 UTC
⚠️
Conflict check required for Sterling Advisory submission.
2 days ago
📊
Q3 Commission schedule updated. Review attached breakdown.
5 days ago
Register New Deal / Proposal
Encrypted Transmission
All submissions are logged, timestamped, and routed to the appropriate divisional deal desk. Please ensure target information aligns with current M&A guidelines.
\n
Broker Resource Center
📜
M&A Guidelines & Criteria
Division-specific thresholds, sector focus, and valuation parameters.
💼
Commission & Fee Structure
Standard Lehman formula adjustments, break schedules, and payment terms.
🔒
Data Room Access Request
Procedure for requesting VDR credentials post-NDA execution.
⚖️
Compliance & Conflict Checks
Mandatory screening protocols, blackout periods, and disclosure requirements.
📞
Deal Desk Directory
Direct contacts for divisional CFOs, M&A heads, and legal counsel.
📊
Market Intelligence Reports
Quarterly sector analysis, valuation benchmarks, and strategic outlooks.

Active Deal Registry

Full deal tracking interface with timeline views, document versioning, and stakeholder assignment.

Secure Virtual Data Room

End-to-end encrypted document exchange. Access requires active NDA and IP whitelisting.

Compliance & NDA Gateway

Manage bilateral NDAs, regulatory disclosures, and conflict-of-interest declarations.